Boundless Bio, Inc.
BOLDNASDAQHealthcareBiotechnology
Regular session
$2.925
−$0.075 · -2.50%
BOLD company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
33
Expensive
Momentum
63
Gaining
Sentiment
53
Mixed
Risk resilience
55
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteBoundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Zachary Hornby
- Listed since
- Mar 28, 2024
- Employees
- 28
Market position
Day range
Current $2.925
52-week range
Current $2.925
- Open
- $3.12
- Previous close
- $3.00
- Volume
- 94.76K
- 0.09× average
- Average volume
- 1.01M
- Average daily volume
- Market cap
- 65.74M USD
- Beta
- 0.38
- Market reference 1
- 50-day average
- $2.4384
- +19.96% above average
- 200-day average
- $1.5545
- +88.17% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 58M USD
- EV / EBITDA
- -1.02×
- Earnings yield
- -216.89%
- Free cash flow yield
- -175.94%
Profitability & efficiency
- Return on equity
- -58.99%
- Return on assets
- -37.05%
- Return on invested capital
- -43.03%
Financial health
- Current ratio
- 8.74×
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 1.25M USD | 1.09M USD | — | — | — |
| Gross profit | −1.25M USD | −1.09M USD | — | — | — |
| Research and development | 44.85M USD | 55.27M USD | 42.64M USD | 37.16M USD | 19.28M USD |
| Selling, general, and administrative | 18.71M USD | 18M USD | 12.16M USD | 9.31M USD | 6.02M USD |
| Operating expenses | 62.3M USD | 72.18M USD | 54.8M USD | 46.47M USD | 25.3M USD |
| Interest income | 5.36M USD | 7.89M USD | 5.28M USD | 668K USD | 96K USD |
| Depreciation and amortization | 1.25M USD | 1.09M USD | 957K USD | 942K USD | 682K USD |
| Operating income | −63.55M USD | −73.27M USD | −54.8M USD | −46.47M USD | −25.3M USD |
| Net income | −58.2M USD | −65.36M USD | −49.43M USD | −45.9M USD | −25.21M USD |
Company facts updated Aug 24, 2026.
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
20 ratingsBOLD news
BOLD peers
ETFs holding BOLD
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 1.11M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $377.21-0.27%
Vanguard Extended Market ETFVXF- Market value
- 380.03K
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $243.36-0.88%
iShares Micro-Cap ETFIWC- Market value
- 178.88K
- Weight
- 0.01%
- AUM
- 1.53B USD
- Expense ratio
- 0.60%
- Price / 1D
- $196.74-0.71%
Continue in GoAI
Research BOLDresearch.disclaimer